Biogen Faces Growth Headwinds Despite Pipeline Progress

Biogen (BIIB) is navigating a precarious transition period as legacy product erosion clashes with the slow ramp-up of its newer therapeutic portfolio. While the company has a history of long-term outperformance, recent financial metrics suggest a period of stagnation and heightened risk. The company's 2025 performance highlighted these struggles, with revenue reaching $9.9 billion—a marginal 2% increase—while adjusted earnings per share fell 7% to $15.28. This decline is primarily attributed to biosimilar competition within its multiple sclerosis (MS) franchise and competitive pressures facing Spinraza, its treatment for spinal muscular atrophy. Growth hopes are currently centered on Leqembi, an Alzheimer's disease treatment co-marketed with Eisai. Biogen's share of Leqembi revenue surged 197% last year to $178 million. The potential shift toward subcutaneous administration for both maintenance and initiation could significantly increase patient adoption by allowing for at-home treatment rather than clinic-based infusions. Beyond Leqembi, Biogen is leveraging a high-dose formulation of Spinraza, as well as newer products like Skyclarys for Friedreich's Ataxia and Zurzuvae for postpartum depression. These assets are intended to diversify revenue streams and stabilize the top line. Despite these advancements, Biogen's own guidance indicates that sales will decrease on a year-over-year basis in 2026. The company remains heavily dependent on the flawless execution of its pipeline to return to meaningful growth, leaving little room for error in its commercial strategy.